FINWIRES · TerminalLIVE
FINWIRES

Top Midday Stories: Micron Shares Soar After Estimate-Topping Earnings Results; Bio-Techne to be Acquired by Merck for $11.3 Billion

By

The Dow Jones Industrial Average and S&P 500 were up in late-morning trading Thursday, while the Nasdaq Composite was down, as investors weighed Micron Technology's (MU) latest earnings results as well as new data from the Federal Reserve's preferred inflation measurement.

The personal consumption expenditures index increased by 0.4% in May, below the 0.5% gain expected and matching April's level, lifting the year-over-year rate to 4.1% from 3.8%, the Bureau of Economic Analysis said Thursday. The core PCE index, which excludes food and gas prices, increased by 0.3%, matching expectations and April's level.

In company news, Micron Technology (MU) reported fiscal Q3 adjusted earnings late Wednesday of $25.11 per diluted share, up from $1.91 a year earlier and above the FactSet consensus analyst estimate of $20.86. Fiscal Q3 revenue was $41.46 billion, up from $9.30 billion a year earlier and above the FactSet consensus of $35.91 billion. For fiscal Q4, the company expects adjusted EPS of $31, plus or minus $1, on revenue of $50 billion, plus or minus $1 billion. Analysts polled by FactSet expect $25.72 and $43.58 billion, respectively. Micron shares were up 12.8% around midday.

Bio-Techne (TECH) has signed a definitive agreement to be acquired by Merck KGaA for $73 a share, representing an enterprise value of $11.3 billion, the companies said Thursday. The proposed transaction has received board approval from Merck, and it's expected to close by late 2026 or early 2027, subject to regulatory and shareholder approvals, the companies said. Bio-Techne shares were up 19.8%.

Apple (AAPL) raised its prices for a number of its MacBooks and iPads as it passes on higher costs for memory and storage to customers, according to media reports Thursday. The tech giant raised the prices on the MacBook Neo, MacBook Air 512GB and MacBook Pro 1T to $699, $1,299, and $1,999 from $599, $1,099 and $1,699, respectively, the reports said. Apple raised the prices on iPad Air 128GB and iPad Pro Wifi 256GB to $749 and $1,199 from $599 and $999, respectively, according to the reports. Apple shares were down 5.2%.

All 32 large banks subject to the Fed's annual stress test have sufficient capital to absorb losses totaling nearly $708 billion and continue lending to businesses and households under hypothetical stressful conditions, the central bank said late Wednesday. JPMorgan Chase (JPM), Goldman Sachs (GS) and Morgan Stanley (MS) all boosted their dividends shortly after the results were announced. JPMorgan plans to increase its quarterly dividend to $1.65 per share from $1.50 for Q3, and it also authorized a new $50 billion share buyback program, effective July 1. Goldman plans to increase its common dividend to $5 per share from $4.50, beginning July 1. Morgan Stanley plans to raise its quarterly dividend to $1.15 per share from $1.00, expected to be declared in Q3. The bank also reauthorized up to $20 billion of a multi-year common equity share buyback program without an expiry date.

Separately, JPMorgan said Thursday that Doug Petno and Troy Rohrbaugh have been named co-presidents of the company, effective immediately. Petno will also now be sole CEO of the company's Commercial & Investment Bank, while Rohrbaugh will be the CEO of Consumer and Community Banking, or CCB. Current CCB CEO Marianne Lake has decided to retire, the company said. Shares of JPMorgan, Goldman and Morgan Stanley were up 2.2%, 1.5% and 2.3%, respectively.

Price: $1182.13, Change: $+134.21, Percent Change: +12.81%

Related Articles

Wire

Arovella Therapeutics Secures Ethics Approval for First-in-Human Study of Blood Cancer Drug Candidate

Arovella Therapeutics (ASX:ALA) received ethics approval from The Alfred and Bellberry Human Research Ethics Committees to begin its phase 1 first-in-human clinical trial of ALA-101 drug candidate, a chimeric antigen receptor invariant natural killer T (CAR-iNKT) cell therapy for patients with relapsed or refractory lymphomas and leukemias, according to a Thursday Australian bourse filing.The trial is expected to involve up to seven clinical sites across Australia and New Zealand, the filing said. It will evaluate the safety, tolerability, and preliminary anti-tumor activity of ALA-101.The company remains on track to begin first patient dosing in the September quarter.Arovella Therapeutics' shares fell past 1% in recent trading on Thursday and earlier hit their lowest since September 2023.

ASX:ALA
Wire

Update: Tourism Holdings Receives Additional Non-Binding Takeover Offer From Unnamed 'Credible Strategic' Buyer; Shares Over Two-Year High

(Updates to add stock movement in the headline and the last paragraph)Tourism Holdings (ASX:THL, NZE:THL) received an additional non-binding indicative offer from an unnamed "credible strategic" buyer to acquire 100% of the company at a proposed price of NZ$3.30 to NZ$3.40 per share, according to a Thursday filing with the New Zealand and Australian bourses.The proposal is subject to customary conditions, including due diligence, board approval, regulatory and third-party consents, and unanimous board recommendation, subject to standard fiduciary carve-outs, per the filing.The company has allowed the bidder to conduct due diligence under a confidentiality agreement while emphasizing that no decision has been made and there is no assurance that a transaction will proceed, the filing said.The company is also engaged in discussions with the BGH consortium on a similar confidentiality agreement to support due diligence, the filing added.The company's shares on the New Zealand bourse rose 12% in Thursday trading and earlier reached their highest level since April 2024, while Australian shares gained 11%.

ASX:THLNZE:THL
Wire

Lockheed Martin Wins Up to $35 Billion Contract to Expand US Missile Defense Production

Lockheed Martin (LMT) won a seven-year US government contract worth up to $35 billion to quadruple production of its Terminal High Altitude Area Defense interceptors.The award is one of the first major multiyear procurement contracts under the Pentagon's new acquisition strategy, Lockheed Martin said Wednesday in a statement.The contract implements a THAAD framework agreement signed in January and is intended to support long-term production scaling and strengthen the missile-defense industrial base for the US and its allies, the company said.Lockheed Martin shares rose 0.9% in after-hours trading.

$LMT